The randomized controlled trial (RCT) provides critical support for evidence-based practice using psychological interventions. The control condition is the principal method of removing the influence of unwanted variables in RCTs. There is little agreement or consistency in the design and construction of control conditions. Because control conditions have variable effects, the results of RCTs can depend as much on control condition selection as on the experimental intervention. The aim of this paper is to present a framework for the selection and design of control conditions for these trials. Threats to internal validity arising from modern RCT methodology are reviewed and reconsidered. The strengths and weaknesses of several categories of control conditions are examined, including the ones that are under experimental control, the ones that are under the control of clinical service providers, and no-treatment controls. Considerations in the selection of control conditions are discussed and several recommendations are proposed. The aim of this paper is to begin to define principles by which control conditions can be selected or developed in a manner that can assist both investigators and grant reviewers.

1.
Chambless DL, Ollendick TH: Empirically supported psychological interventions: controversies and evidence. Annu Rev Psychol 2001;52:685–716.
2.
Cuijpers P, van Straten A, Warmerdam L, Smits N: Characteristics of effective psychological treatments of depression: a meta-regression analysis. Psychother Res 2008;18:225–236.
3.
Kazdin AE: Methodology, design, and evaluation in psychotherapy research; in Bergin AE, Garfield SL (eds): Handbook of Psychotherapy and Behavior Change, ed 4. New York, Wiley, 1994.
4.
Kirsch I: Placebo psychotherapy: synonym or oxymoron? J Clin Psychol 2005;61:791–803.
5.
Lohr JM, Olatunji BO, Parker L, DeMaio C: Experimental analysis of specific treatment factors: efficacy and practice implications. J Clin Psychol 2005;61:819–834.
6.
Campbell DT, Stanley JC: Experimental and Quasi-Experimental Designs for Research. Chicago, Rand McNally, 1966.
7.
Shadish WR, Cook TD, Campbell DT: Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, Houghton Mifflin, 2002.
8.
Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, Ogedegbe G, Orwig D, Ernst D, Czajkowski S: Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychol 2004;23:443–451.
9.
Crits-Christoph P, Baranacki K, Kurcias JS, Beck AT, Carroll K, Perry K, Luborsky L, McLellan T, Woody GE, Thompson L, Gallagher D, Zitrin C: Meta-analysis of therapist effects in psychotherapy outcome studies. Psychother Res 1991;1:81–91.
10.
Cottraux J, Note I, Yao SN, de Mey-Guillard C, Bonasse F, Djamoussian D, Mollard E, Note B, Chen Y: Randomized controlled comparison of cognitive behavior therapy with Rogerian supportive therapy in chronic post-traumatic stress disorder: a 2-year follow-up. Psychother Psychosom 2008;77:101–110.
11.
Luborsky L, Diguer L, Seligman DA, Rosenthal R, Krause ED, Johnson S, Halperin G, Bishop M, Berman JS, Schweizer E: The researcher’s own therapy allegiances: a ‘wild card’ in comparisons of treatment efficacy. Clin Psychol Sci Pract 1999;6:95–106.
12.
Gaudiano BA, Herbert JD: Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom 2005;74:17–25.
13.
Walach H, Bosch H, Lewith G, Naumann J, Schwarzer B, Falk S, Kohls N, Haraldsson E, Wiesendanger H, Nordmann A, Tomasson H, Prescott P, Bucher HC: Effectiveness of distant healing for patients with chronic fatigue syndrome: a randomised controlled partially blinded trial (EUHEALS). Psychother Psychosom 2008;77:158–166.
14.
Harris KB, Miller WR: Behavioral self-control training for problem drinkers: components of efficacy. Psychol of Addict Behav 1990;4:82–90.
15.
Schmidt MM, Miller WR: Amount of therapist contact and outcome in a multidimensional depression treatment program. Acta Psychiatr Scand 1983;67:319–332.
16.
Basham RB: Scientific and practical advantages of comparative design in psychotherapy outcome research. J Consult Clin Psychol 1986;54:88–94.
17.
Hardy GE, Barkham M, Shapiro DA, Reynolds S, Rees A, Stiles WB: Credibility and outcome of cognitive-behavioural and psychodynamic-interpersonal psychotherapy. Br J Clin Psychol 1995;34:555–569.
18.
Barlow DH: Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York, Builford, 2002.
19.
Borkovec TD, Costello E: Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993;61:611–619.
20.
Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol 1999;67:194–200.
21.
Meehl PE: Psychotherapy. Annu Rev Psychol 1955;6:129–131.
22.
Paul GL: Behavior modification research: design and tactics; in Franks CM (ed): Behavior Therapy: Appraisal and Status. New York, McGraw-Hill, 1966, pp 29–62.
23.
Kazdin A: Research Design in Clinical Psychology. New York, Harper & Row, 1980.
24.
Frank JD, Frank JB: Persuasion and Healing: A Comparative Study of Psychotherapy, ed 3. Baltimore, Hopkins University Press, 1991.
25.
Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, Tasch ET: Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 2005;62:1007–1014.
26.
Jacob RG, Shapiro AP, O’Hara P, Portser S, Kruger A, Gatsonis C, Ding Y: Relaxation therapy for hypertension: setting-specific effects. Psychosom Med 1992;54:87–101.
27.
Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, Gabbay M, Tarrier N, Addington-Hall J: Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. 1. Clinical effectiveness. BMJ 2000;321:1383–1388.
28.
Unutzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, Hoffing M, Della Penna RD, Noel PH, Lin EH, Arean PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002;288:2836–2845.
29.
Mohr DC, Likosky W, Bertagnolli A, Goodkin DE, Van Der Wende J, Dwyer P, Dick LP: Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68:356–361.
30.
Simon GE, Ludman EJ, Tutty S, Operskalski B, Von Korff M: Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA 2004;292:935–942.
31.
Reynolds CF 3rd, Degenholtz H, Parker LS, Schulberg HC, Mulsant BH, Post E, Rollman B: Treatment as usual (tau) control practices in the prospect study: managing the interaction and tension between research design and ethics. Int J Geriatr Psychiatry 2001;16:602–608.
32.
Gelder MG, Marks IM: Severe agoraphobia: a controlled prospective trial of behaviour therapy. Br J Psychiatry 1966;112:309–319.
33.
Peden AR, Rayens MK, Hall LA, Beebe LH: Preventing depression in high-risk college women: a report of an 18-month follow-up. J Am Coll Health 2001;49:299–306.
34.
Atkins CJ, Kaplan RM, Timms RM, Reinsch S, Lofback K: Behavioral exercise programs in the management of chronic obstructive pulmonary disease. J Consult Clin Psychol 1984;52:591–603.
35.
Herbert JD, Gaudiano BA: Moving from empirically supported treatment lists to practice guidelines in psychotherapy: the role of the placebo concept. J Clin Psychol 2005;61:893–908.
36.
Wellek S: Testing Statistical Hypotheses of Equivalence. Boca Raton, CRC Publishers, 2002.
37.
DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O’Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R: Cognitive therapy vs. medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62:409–416.
38.
US Food and Drug Administration: Title 21, section 321.21, phases of an investigation: Code of Federal Regulations. 2005, 21CFR312.21.
39.
Rounsaville BJ, Carroll KM, Onken LS: A stage model of behavioral therapies research: getting started and moving on from stage I. Clin Psychol Sci Pract 2001;8:133–142.
40.
Lilienfeld SO: Psychological treatments that cause harm. Perspect Psychol Sci 2007;2:53–70.
41.
Mohr DC: Negative outcome in psychotherapy: a critical review. Clin Psychol Sci Pract 1995;2:1–27.
42.
Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA: Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 2006;63:484–489.
43.
Glasgow RE, Davidson KW, Dobkin PL, Ockene J, Spring B: Practical behavioral trials to advance evidence-based behavioral medicine. Ann Behav Med 2006;31:5–13.
44.
Velazquez EJ, Califf RM: All that glitters is not gold. Lancet 2000;355:1568–1569.
45.
Kazdin AE: The meanings and measurement of clinical significance. J Consult Clin Psychol 1999;67:332–339.
46.
Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR, Fleshner MR, Gandevia SC, Gomez-Pinilla F, Greenwood BN, Hillman CH, Kramer AF, Levin BE, Moran TH, Russo-Neustadt AA, Salamone JD, Van Hoomissen JD, Wade CE, York DA, Zigmond MJ: Neurobiology of exercise. Scand J Med Sci Sports 2006;16:470.
47.
Bola JR, Mosher LR: Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis 2003;191:219–229.
48.
Spooner C, Mattick RP, Noffs W: Outcomes of a comprehensive treatment program for adolescents with a substance-use disorder. J Subst Abuse Treat 2001;20:205–213.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.